Free overnight shipping in all 50 states
HealthRx.com
Foundation · No. 01

Compounded Semaglutide

a once-weekly GLP-1 receptor agonist

0.25 MG → 2.4 MG · 4-week vial supply

From
$99/mo
$3.30 / day
Brand-name Wegovy cash
$1,349
$45 / day
Start my free visitCommon questions
A modern medical injector pen, Compounded Semaglutide
Fig. 01 · Compounded SemaglutideLOT 50087439

Semaglutide is the first GLP-1 weight-management compound to enter wide clinical use. It is the active molecule in branded Wegovy® and Ozempic®. The HealthRX.com preparation is compounded by a licensed pharmacy under Section 503A on a valid, patient-specific prescription.

Mechanism · 02

How it works in the body

Semaglutide is a long-acting synthetic analog of human GLP-1, the gut hormone released after a meal. By binding to the GLP-1 receptor, it slows gastric emptying, amplifies the body's satiety signaling in the hypothalamus, and improves glucose-dependent insulin secretion. The result is reduced appetite, quieter food noise, and gradual sustained weight loss.

Titration · 03

The dose ladder.

WeekDoseNote
Weeks 01–040.25 mg / weekInitiation. Lowest dose, designed to acclimate the gut.
Weeks 05–080.5 mg / weekFirst dose escalation. Most appetite changes start here.
Weeks 09–121.0 mg / weekProvider check-in. Re-evaluate tolerance and response.
Weeks 13–161.7 mg / weekTherapeutic dose for many patients.
Weeks 17+2.4 mg / weekMaintenance dose, only if tolerated and clinically appropriate.
Documented · 04

What the trials show.

14.9%
average body-weight loss at 68 weeks
STEP-1, NEJM 2021
86%
of participants lost ≥5% body weight
STEP-1, NEJM 2021
32%
reduction in major adverse cardiovascular events (SELECT)
SELECT, NEJM 2023
Risks · 05

Side effects, honestly.

Common

  • · Nausea (most common during titration)
  • · Diarrhea or constipation
  • · Decreased appetite (the therapeutic effect)
  • · Mild headache, fatigue
  • · Burping, indigestion

Serious

  • · Pancreatitis (rare)
  • · Gallbladder disease
  • · Hypoglycemia (especially with other diabetes medications)
  • · Possible thyroid C-cell tumors (animal studies in rats; relevance to humans unknown)
Fit · 06

Who it's for. Who it isn't.

Suitable for

  • · Adults with BMI ≥ 30, or BMI ≥ 27 with a weight-related condition
  • · Patients new to GLP-1 therapy
  • · Patients seeking the most studied compound in the category

Not suitable for

  • · Personal or family history of medullary thyroid carcinoma
  • · Multiple Endocrine Neoplasia syndrome type 2 (MEN-2)
  • · History of severe pancreatitis
  • · Pregnant or breastfeeding
  • · Severe gastrointestinal disease
Common questions · 07

Questions, answered.

How much does compounded semaglutide cost at HealthRX.com?

Compounded semaglutide plans start at $99/mo with the annual option. The price you see at checkout is the price billed. No insurance required.

Is compounded semaglutide the same as Wegovy or Ozempic?

Semaglutide is the active molecule in branded Wegovy and Ozempic. The HealthRX.com preparation is compounded by a licensed 503A pharmacy on a valid, patient-specific prescription. It is not the branded product.

How much weight can I expect to lose on semaglutide?

In the STEP-1 trial, adults lost an average of 14.9% of body weight at 68 weeks, and 86% lost at least 5% of body weight. Individual results vary and depend on dose, tolerance, and lifestyle.

How is semaglutide dosed?

Semaglutide is a once-weekly injection titrated from 0.25 mg up to a maintenance dose (up to 2.4 mg) over several months, escalated only as tolerated and clinically appropriate under provider supervision.

Who should not take semaglutide?

Semaglutide is not appropriate for people with a personal or family history of medullary thyroid carcinoma or MEN-2, a history of severe pancreatitis, or during pregnancy or breastfeeding. A licensed clinician reviews your history before prescribing.

Citations · 08

The published evidence.

  1. 01Wilding et al. Once-weekly semaglutide in adults with overweight or obesity (STEP-1). NEJM 2021.
  2. 02Davies et al. STEP-2: semaglutide in adults with type 2 diabetes. Lancet 2021.
  3. 03Lincoff et al. SELECT trial: semaglutide and cardiovascular outcomes in obesity. NEJM 2023.
  4. 04FDA Prescribing Information: Wegovy and Ozempic (semaglutide).
Start my free visit

Researching your options? Explore the full GLP-1 medicine library or compare compounded semaglutide and compounded tirzepatide.